Vol 3, No 6 (2007)
Guidelines / Expert consensus
Published online: 2008-05-08
Systemic therapy of colorectal cancer - consensus based on the results of clinical trials
Onkol. Prak. Klin 2007;3(6):267-285.
Abstract
Colorectal cancer represents a major health problem in Poland, accounting for over 13 000 new cases
diagnosed annually. The treatment options in colorectal cancer have evolved significantly over the last
decade, with several new cytotoxic and molecularly targeted agents approved for the treatment of this
disease. These advances have brought a clear improvement in survival of patients. The efficacy of new
cytotoxic drugs (irinotecan, oxaliplatin and oral fluoropyrimidines), both in the adjuvant and palliative
settings, have been confirmed in the randomised studies. The advent of monoclonal antibodies (bevacizumab,
cetuximab and panitumumab) may further broaden the scope of therapeutic methods in metastatic
disease, however the clinical application of these compounds is still limited. Despite these achievements,
the oncology community still awaits answers to numerous questions on the optimal use of newly
developed systemic treatment options. This article reviews available options of systemic therapy with the
aim of assisting clinicians in their daily practice.
Keywords: colorectal cancersystemic therapyadjuvant therapypalliative therapy